Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Condition(s):Idiopathic Pulmonary Fibrosis, Acute Fatal FormLast Updated:August 8, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Idiopathic Pulmonary Fibrosis, Acute Fatal FormLast Updated:August 8, 2023Recruiting
Condition(s):Idiopathic Pulmonary Fibrosis, Interstitial Lung DiseaseLast Updated:November 27, 2023Recruiting
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:November 9, 2023Recruiting
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:April 13, 2022Active, not recruiting
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:August 10, 2021Completed
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:July 28, 2016Unknown status
Condition(s):Ambulatory IPFLast Updated:January 27, 2022Completed
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:December 23, 2016Completed
Condition(s):Idiopathic Pulmonary Fibrosis (IPF)Last Updated:May 12, 2020Completed
Condition(s):Idiopathic Pulmonary Fibrosis; Interstitial Lung DiseaseLast Updated:March 26, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.